BMRN Financial Facts
Equity in the loss of BioMarin/Genzyme LLC: -104KInterest income: 1.63M
See Full Income Statement
Property, plant and equipment, net: 729.84M
Long-term deferred tax assets: 288.01M
See Full Balance Sheet
BioMarin Pharmaceutical Inc. (BMRN) Earnings
|
Expand Research on BMRN
| Next EPS Date | 7/29/24 *Est. | EPS Growth Rate | +18.3% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +125.4% | Revenue Growth Rate | +8.8% *Last Qtr. |
| Average % Move 1-Wk after EPS | -0.7% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/2/18 |  |
Q218 | -$0.09 | -$0.17 | +$0.08 | $372.8B | $3.62B | = |  | | Details |
| 4/24/24 | Q124 | $0.71 | $0.32 | +$0.39 | $649M | $649.27M | = | | | Details | |
| 2/22/24 | Q423 | $0.49 | $0.20 | +$0.29 | $646.2M | $639.26M | = | | | Details | |
| 4/26/23 | Q123 | $0.60 | $0.21 | +$0.39 | $596.4M | $571.33M | = | | | Details | |
| 7/31/23 | Q223 | $0.54 | $0.23 | +$0.31 | $595.3M | $595.22M | = | | | Details | |
| 11/1/23 | Q323 | $0.46 | $0.23 | +$0.23 | $581.3M | $607.5M | = | | | Details | |
| 2/27/23 | Q422 | $0.00 | -$0.06 | +$0.06 | $537.5M | $537.62M | = | | | Details | |
| 8/3/22 | Q222 | $0.15 | $0.03 | +$0.12 | $533.8M | $520.35M | = | | | Details |
